Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2022
Price :
$35
*
At a glance
- Drugs ASN 100 (Primary)
- Indications Pneumonia; Staphylococcal infections
- Focus Therapeutic Use
- Sponsors Arsanis
- 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
- 09 Nov 2018 According to an Arsanis Biosciences media release, follow-up visits for all 154 patients who were enrolled in this study were completed and the trial database was locked during the third quarter of 2018.
- 28 Jun 2018 Arsanis Biosciences has discontinued this trial following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC). The DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion and recommended that trial enrollment be discontinued. The company intends to conduct follow-up visits on all patients dosed with ASN100, according to an Arsanis Biosciences media release.